Wednesday, November 19, 2025 11:52:40 PM
Great post from stocktwits:::::::::
😍4. US Manufacturing: The BIG One🥰
Q2 = down to two finalists.
Q3 = site selected, responsibilities assigned, and hiring has begun.
You do NOT start building and staffing a US manufacturing footprint if you think the UK approval is still questionable.
This is “global rollout mode,” not “wait and see.”
5. Compassionate Use Expansion
They’re now pursuing multiple hospital arrangements and expanded access programs.
Hospitals don’t sign on unless they believe commercial approval is near.
6. DCVax-Direct Just Leveled Up
Q3 shows:
• New clinical trial designs
• Additional agents
• Multiple routes of administration
• Pre-conditioning regimens
This is a pipeline being built behind DCVax-L — not a one-drug company.
7. Overall Tone Shift = They’re Preparing for Market, Not Hoping for it
Everything in Q3 reads like:
• Infrastructure build-out
• Staffing
• Expansion
• Scaling
• Commercial readiness
Not theoretical. Not speculative. Not delayed.
Nov 15, 2025 7:50 AM
😍4. US Manufacturing: The BIG One🥰
Q2 = down to two finalists.
Q3 = site selected, responsibilities assigned, and hiring has begun.
You do NOT start building and staffing a US manufacturing footprint if you think the UK approval is still questionable.
This is “global rollout mode,” not “wait and see.”
5. Compassionate Use Expansion
They’re now pursuing multiple hospital arrangements and expanded access programs.
Hospitals don’t sign on unless they believe commercial approval is near.
6. DCVax-Direct Just Leveled Up
Q3 shows:
• New clinical trial designs
• Additional agents
• Multiple routes of administration
• Pre-conditioning regimens
This is a pipeline being built behind DCVax-L — not a one-drug company.
7. Overall Tone Shift = They’re Preparing for Market, Not Hoping for it
Everything in Q3 reads like:
• Infrastructure build-out
• Staffing
• Expansion
• Scaling
• Commercial readiness
Not theoretical. Not speculative. Not delayed.
Nov 15, 2025 7:50 AM
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
